Corvus Pharmaceuticals (CRVS)

Executive Summary

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company developing precision small-molecule therapies for difficult-to-treat cancers and inflammatory diseases. Its lead asset, soquelitinib (CPI-818), is a potent and selective ITK inhibitor being investigated in T-cell lymphoma and atopic dermatitis. In T-cell lymphoma, a Phase 1 trial (NCT03952078) is nearing completion, with data expected in mid-2026. The company is also advancing a Phase 3 trial (NCT06561048) of soquelitinib combined with chemotherapy in peripheral T-cell lymphoma, which began recruiting in late 2024. In atopic dermatitis, a Phase 1 trial (NCT06345404) finished in February 2026, and a Phase 2 study (NCT07441395) initiated in early 2026. Corvus also has an early-stage asset, ciforadenant (A2A receptor antagonist), with prior Phase 1 data in renal cell cancer. The company’s near-term value is tied to clinical data readouts for soquelitinib across multiple indications, though the stock remains speculative given early-stage programs and no approved products.

Upcoming Catalysts (preview)

• Q2 2026Phase 1 data for soquelitinib (CPI-818) in T-cell lymphoma65% success
• Q2 2026Phase 1 results for soquelitinib in atopic dermatitis60% success
• 2026Phase 3 enrollment update for soquelitinib in peripheral T-cell lymphoma70% success